Navigation Links
Research promising for cystic fibrosis
Date:3/18/2008

Toronto, ON. New U of T research holds promise for developing innovative therapies against cystic fibrosis and may also serve as a model for future therapies against the HIV virus.

Led by Professor Igor Stagljar, University of Toronto scientists have identified several compounds that block activity of a key protein (exoenzymeS or ExoS). One of these compounds, exosin, significantly inhibited infections in mammalian cells, showing promise for increasing the effectiveness of antibiotics in the treatment of chronic and acute bacterial respiratory infections in cystic fibrosis patients.

Past studies have shown it is possible to prevent or delay the onset of certain chronic or deadly infections in cystic fibrosis patients with early antibiotic treatment. But the current availability of antibiotics against Pseudomonas aeruginosa, a pathogen that can cause urinary tract infections, respiratory system infections, dermatitis, soft tissue infections, bacteremia, bone and joint infections, gastrointestinal infections and a variety of systemic infections, is limited and the pathogen shows signs of drug resistance.

In an article published in the online edition of the journal PLoS Genetics, a team of investigators, including first author and U of T graduate student Anthony Arnoldo, identified several drugs that block a Pseudomonas aeruginosa toxin called ExoS.

"These studies created a road map to the rational design of more potent, highly selective inhibitors against other similar toxins using a totally novel yeast-based approach," says lead author Stagljar. This innovative approach is an important advance, not only for the value it may have in cystic fibrosis treatment, but also because this technique could be used to design novel therapies for any bacterial pathogen as well as the HIV virus.

In the next phase of their research, Stagljar and his colleagues plan to test the action of their inhibitors in an animal model of
'/>"/>

Contact: April Kemick
april.kemick@utoronto.ca
416-978-5949
University of Toronto
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
5. New research shows how chronic stress worsens neurodegenerative disease course
6. New research explores newborn in-hospital weight loss
7. Research may unlock mystery of autisms origin in the brain
8. Bipolar disorder relapses halved by Melbourne researchers
9. HIVs impact in Zimbabwe explored in new research
10. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
11. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... is common during the holidays, but there are strategies that ... "Don,t arrive at a party hungry. It may seem logical ... a party, but deprivation leads to hunger, and hunger leads ... in Mount Kisco, N.Y., said in a hospital news release. ... even to have a snack before attending a party when ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... Thousands of transvaginal mesh lawsuits ( ... number of multidistrict litigations currently underway in U.S. District ... reports. According to an Order issued on December 2, ... Status Conference in all of the proceedings on January ... to submit a proposed agenda to the Court by ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
(Date:12/25/2014)... Rosa, CA (PRWEB) December 25, 2014 ... department visits and 2 million hospital admissions across the ... and Prevention ). The CDC’s National Hospital Ambulatory ... departments through a survey conducted in 2010. They estimated ... department visits that resulted in a primary diagnosis of ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... sure they,ve made the right choice , ... ... annual Medicare enrollment has ended, some Medicare Advantage beneficiaries can ... period. That information comes from Allsup , a leading ...
... Jan. 12 Acclarent, Inc., a leading,medical technology ... address conditions affecting the ear, nose and,throat, announced ... financing round.,Acclarent intends to use the proceeds to ... as on-going investment in product,development and clinical studies. ...
... recall of King Nut brand after Minn. officials find bacteria ... been sickened , , SUNDAY, Jan. 11 (HealthDay News) -- ... for two brands of peanut butter after health officials in ... a tub of peanut butter that is distributed to schools ...
... giving guests a reason to be cheerful by announcing a winter sale ... ... (PRWEB) January 11, 2009 -- The Linwood Group has revealed that it ... can access its first rate facilities., , ,From Christmas through to the ...
... Ohio-based manufacturer and long-standing leader in the development of ergonomic ... with a solution to a unique furnishing challenge it faced ... ... Bowling Green, OH (PRWEB) January 10, 2009 ...
... The Asthma and Allergy Foundation of America (AAFA) announces ... been appointed to the Council of the National Institute ... the National Institutes of Health (NIH), for a four-year ... provides a diverse perspective on science, health and the ...
Cached Medicine News:Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 2Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 3Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 4Health News:Medicare Advantage Open Enrollment Offers One-Time Chance to Change Your Mind: Allsup Outlines Rules for Switching Plans 5Health News:Acclarent, Inc. Closes $26 Million Financing 2Health News:Peanut Butter Recalled as Salmonella Search Continues 2Health News:Peanut Butter Recalled as Salmonella Search Continues 3Health News:Peanut Butter Recalled as Salmonella Search Continues 4Health News:Linwood Group Setting Price Benchmark for Alcohol Rehab 2Health News:BioFit 1Y Takes the Plunge to Fill Undersea Seating Role for NOAA 2Health News:Asthma & Allergy Foundation CEO Appointed to NIH Council 2
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 /PRNewswire/ ... (NASDAQ: ENDP ) (TSX: ENL), and BioDelivery ... today that they have submitted a New Drug Application ... Food and Drug Administration (FDA).  Buprenorphine HCl Buccal Film ... enough to require daily, around-the-clock, long-term opioid treatment and ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... 22, 2014 Apnea Sciences ( www.apneasciences.com ) ... Aliso Viejo , California.  Jimmy ... tremendous growth and worldwide expansion, a new facility with ... the anti snore cure have exceeded our expectations and ... are now in 23 countries and will be increasing ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... to Show That Extended,Thromboprophylaxis Reduces VTE Risk ... 44% , PARIS, July 8, 2007 /PRNewswire-FirstCall/ ... (EXtended CLinical,prophylaxis in Acutely Ill Medical patients) ... in acutely ill medical patients,with reduced mobility ...
... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
Cached Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
Kit for the Preparation of Technetium Tc 99m Sestamibi for injection...
Straight Tip, Measures from 0mm to 20mm in 1mm Increments, Readable on Both Sides, Thumbscrew Lock Holds Desired Setting; in Titanium....
Very fine, blunt tip....
... The e.cam duet Signature Series ... and PET FDG imaging applications. The system ... capability with the features and flexibility of ... in one unit.,The e.cam duet ...
Medicine Products: